<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PDGFR-Beta Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>PDGFRB</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>PDGFR-Beta</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=PDGFRB" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimers_disease" style="color:#ef9a9a">Alzheimers_disease</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-73e4340b" style="color:#ce93d8" title="Score: 0.43">Pericyte Contractility Reset via Selecti...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">365 edges</a></td>
</tr>
</table>
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PDGFR-Beta Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>PDGFRB</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>PDGFR-Beta</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=PDGFRB" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/alzheimers_disease" style="color:#ef9a9a">Alzheimers_disease</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-73e4340b" style="color:#ce93d8" title="Score: 0.43">Pericyte Contractility Reset via Selecti...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">365 edges</a></td>
</tr>
</table>
.infobox .infobox-protein
!!! Info
PDGFR-beta (PDGFRB) is a receptor tyrosine kinase that translates platelet-derived growth-factor ligands into pericyte survival, vascular maturation, and neurovascular homeostasis programs.[@andrae2008][@tallquist2004] In the adult CNS, PDGFRB expression is highly enriched in mural-cell lineages, making it one of the most biologically specific molecular handles for pericyte status in neurodegeneration studies.[@bell2010][@bell2010a] This receptor has become central to Alzheimer's and vascular-neurodegeneration research because blood-brain barrier failure and capillary dysfunction are now recognized as early contributors to cognitive decline.[@nation2019][@bell2020]
PDGFRB is a single-pass transmembrane RTK with extracellular Ig-like ligand-binding domains and an intracellular split kinase domain.[@andrae2008] Ligand binding induces receptor dimerization and autophosphorylation, then engages canonical pathways including PI3K-AKT, RAS-MAPK, PLC-gamma, SRC-family signaling, and cytoskeletal remodeling cascades.[@tallquist2004]
In brain vascular units, this signaling logic supports:
Disruption of PDGF-B/PDGFRB signaling in model systems causes severe pericyte deficits and BBB malformation, establishing this axis as non-redundant for cerebrovascular integrity.[@bell2010]
In mature brain, reduced pericyte function and impaired PDGFRB signaling are associated with leakage, inflammatory entry, and impaired clearance environments that can intensify proteinopathy-related toxicity.[@bell2010a][@nation2019]
Soluble/CSF PDGFRB measures are widely used as pericyte-injury surrogates in translational studies. While assay harmonization remains an issue, PDGFRB-linked markers are increasingly integrated with imaging and fluid biomarker panels in early cognitive decline research.[@nation2019][@sweeney2018]
Human data show BBB breakdown can precede overt dementia symptoms, and APOE4 carriers display stronger neurovascular vulnerability signatures.[@nation2019][@bell2020] PDGFRB sits at the center of this biology through its pericyte dependence, making it a mechanistically grounded target for vascular-first intervention strategies.
Although direct PDGFRB-targeted trials in PD/PSP/CBS are limited, the pathway intersects with disease-relevant mechanisms including capillary dysfunction, metabolic stress, and neuroinflammatory amplification. PDGF-BB translational efforts in PD reinforce feasibility of pathway-level modulation.[@paul2015][@su2016]
Pathogenic PDGFRB variants are linked to primary familial brain calcification and related movement/cognitive syndromes, highlighting that receptor dysfunction can itself produce progressive CNS pathology.[@nicolas2013][@keller2013]
The dominant neurodegeneration hypothesis is to restore pericyte-neurovascular resilience rather than drive strong proliferative signaling. This requires carefully titrated pathway support, not maximal receptor stimulation.[@tallquist2004][@su2016]
In practical terms, most clinical-forward approaches currently modulate the axis through ligands (for example PDGF-BB) or downstream vascular-protective programs, with PDGFRB engagement assessed via biomarker panels.[@paul2015][@su2016]
In oncology and fibrotic disease, PDGFRB inhibition is common; in neurodegeneration this is usually undesirable unless there is a distinct proliferative pathology. Translational protocol design must explicitly separate these contexts.[@andrae2008]
Because PDGFRB regulates proliferative and vascular remodeling programs, neurodegeneration trials should include: